Monday, September 26, 2022
HomeBiotechnologyGigaGen Awarded Contract by U.S. Division of Protection to Uncover Artificial Human...

GigaGen Awarded Contract by U.S. Division of Protection to Uncover Artificial Human Antibody Remedies for Excessive-Precedence Toxins and Pathogens


Final Up to date on September 15, 2022 by GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology firm advancing transformative antibody medicine for immune deficiencies, infectious ailments and checkpoint resistant cancers, and a subsidiary of Grifols, introduced as we speak it has entered right into a contract with the U.S. Division of Protection’s (DOD) Joint Program Government Workplace for Chemical, Organic, Radiological and Nuclear Protection (JPEO-CBRND) to display the utility of its first-in-class recombinant human polyclonal antibody discovery platform towards organic threats of curiosity to the DOD.

The JPEO-CBRND awarded GigaGen this Prototype Settlement below the SPARK program, an concept incubator that fuels innovation and drawback fixing by offering funding for doubtlessly transformative tasks. As a part of this award, GigaGen will display its platform’s capabilities by producing recombinant human hyperimmune merchandise that concentrate on DOD-priority pathogens, together with a recombinant polyclonal antibody drug designed to neutralize botulinum neurotoxins A and B, with excessive efficiency and navy utility. The settlement can even enable the JPEO-CBRND to judge GigaGen’s platform towards further organic threats, and assist purposeful testing, manufacturing, and scientific analysis of recombinant polyclonal medicine that meet particular efficiency aims.

“We’re proud to be working carefully with the DOD to develop new and improved medical countermeasures towards naturally rising and intentional organic threats,” stated Carter Keller, a senior vice chairman at Grifols and head of GigaGen. “Our novel expertise platforms allow first-in-class recombinant polyclonal antibody medicine that mix the pace and scale of recombinant antibody manufacturing with the effectiveness of broadly neutralizing polyclonal antibody therapies. We look ahead to utilizing our platform to display the fast response to pathogenic toxins like botulinum neurotoxins A and B, in addition to different high-priority pathogens.”

About GrifolsGrifols is a world healthcare firm based in Barcelona in 1909 dedicated to enhancing the well being and well-being of individuals world wide. A frontrunner in important plasma-derived medicines and transfusion drugs, the corporate develops, produces and offers modern healthcare providers and options in additional than 110 international locations.

Affected person wants and our ever-growing information of many continual, uncommon and prevalent ailments, generally life-threatening, drive our innovation in plasma-based therapies and different biopharmaceuticals to reinforce high quality of life. Grifols is targeted on treating circumstances throughout a broad vary of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious ailments.

A pioneer within the plasma {industry}, Grifols continues to develop its community of donation facilities, the world’s largest with over 400 throughout North America, Europe, Africa and the Center East and China.

As a acknowledged chief in transfusion drugs, Grifols gives a complete portfolio of options designed to reinforce security from donation to transfusion, along with scientific diagnostic applied sciences. We offer high-quality organic provides for life-science analysis, scientific trials, and for manufacturing pharmaceutical and diagnostic merchandise. As well as, the corporate provides instruments, info and providers that allow hospitals, pharmacies and healthcare professionals to effectively ship skilled medical care.

Grifols, with greater than 27,000 staff in additional than 30 international locations and areas, is dedicated to a sustainable enterprise mannequin that units the usual for steady innovation, high quality, security, and moral management.

In 2021, Grifols’ financial affect in its core international locations of operation was EUR 7.7 billion. The corporate additionally generated 141,500 jobs, together with oblique and induced.

The corporate’s class A shares are listed on the Spanish Inventory Trade, the place they’re a part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ:GRFS).

GigaGen is advancing transformative antibody medicine for immune deficiency, infectious ailments and checkpoint resistant cancers by leveraging industry-leading, single-cell applied sciences. Its novel expertise platforms uniquely seize and recreate full immune repertoires as purposeful antibody libraries. This method has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the remedy of infectious ailments. As well as, GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo via a singular mechanism of motion.

For extra info, please go to or

Media Contacts:Monica Rouco Molina, Ph.D. LifeSci Tel: +1-929-469-3850

Grifols Press Workplacemedia@grifols.comTel. +34 93 571 00 02

LEGAL DISCLAIMERThe info and figures contained on this report that don’t seek advice from historic knowledge are “future projections and assumptions”. Phrases and expressions akin to “consider”, “hope”, “anticipate”, “predict”, “anticipate”, “intend”, “ought to”, “will search to attain”, “it’s estimated”, “future” and related expressions, in as far as they relate to the Grifols group, are used to determine future projections and assumptions. These expressions mirror the assumptions, hypotheses, expectations and predictions of the administration workforce on the time of scripting this report, and these are topic to quite a lot of components that imply that the precise outcomes could also be materially completely different. The long run outcomes of the Grifols group may very well be affected by occasions referring to its personal actions, akin to a scarcity of provides of uncooked supplies for the manufacture of its merchandise, the looks of competitor merchandise available on the market, or adjustments to the regulatory framework of the markets wherein it operates, amongst others. On the date of compiling this report, the Grifols group has adopted the mandatory measures to mitigate the potential affect of those occasions. Grifols, S.A. doesn’t settle for any obligation to publicly report, revise or replace future projections or assumptions to adapt them to occasions or circumstances subsequent to the date of scripting this report, besides the place expressly required by the relevant laws. This doc doesn’t represent a suggestion or invitation to purchase or subscribe shares in accordance with the provisions of the next Spanish laws: Royal Legislative Decree 4/2015, of 23 October, approving recast textual content of Securities Market Legislation; Royal Decree Legislation 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any rules creating this laws. As well as, this doc doesn’t represent a suggestion of buy, sale or trade, or a request for a suggestion of buy, sale or trade of securities, or a request for any vote or approval in some other jurisdiction. The knowledge included on this doc has not been verified nor reviewed by the exterior auditors of the Grifols group.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments